Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1 by Lückmann, Michael et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1
Lückmann, Michael; Trauelsen, Mette; Bentsen, Marie A; Nissen, Tinne A D; Martins, Joao;
Fallah, Zohreh; Nygaard, Mads M; Papaleo, Elena; Lindorff-Larsen, Kresten; Schwartz, Thue
W; Frimurer, Thomas M
Published in:
Proceedings of the National Academy of Sciences of the United States of America
DOI:
10.1073/pnas.1811066116
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Lückmann, M., Trauelsen, M., Bentsen, M. A., Nissen, T. A. D., Martins, J., Fallah, Z., ... Frimurer, T. M. (2019).
Molecular dynamics-guided discovery of an ago-allosteric modulator for GPR40/FFAR1. Proceedings of the
National Academy of Sciences of the United States of America, 116(14), 7123-7128.
https://doi.org/10.1073/pnas.1811066116
Download date: 03. Feb. 2020
Molecular dynamics-guided discovery of an ago-
allosteric modulator for GPR40/FFAR1
Michael Lückmanna,b, Mette Trauelsena, Marie A. Bentsena, Tinne A. D. Nissena, Joao Martinsc, Zohreh Fallaha,d,
Mads M. Nygaarde, Elena Papaleoe,f, Kresten Lindorff-Larsenc, Thue W. Schwartza,b, and Thomas M. Frimurera,f,1
aNovo Nordisk Foundation Center for Basic Metabolic Research, University of Copenhagen, DL-2200 Copenhagen, Denmark; bDepartment of Biomedical Sciences,
University of Copenhagen, DK-2200 Copenhagen, Denmark; cDepartment of Biology, University of Copenhagen, DK-2200 Copenhagen, Denmark; dSchool of Nano
Science, Institute for Research in Fundamental Sciences, 19395-5531 Tehran, Iran; eComputational Biology Laboratory, Danish Cancer Society Research Center,
DK-2100 Copenhagen, Denmark; and fNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, DK-2200 Copenhagen, Denmark
Edited by Barry Honig, Howard Hughes Medical Institute, Columbia University, New York, NY, and approved February 14, 2019 (received for review June
28, 2018)
The long-chain fatty acid receptor FFAR1/GPR40 binds agonists in
both an interhelical site between the extracellular segments of
transmembrane helix (TM)-III and TM-IV and a lipid-exposed groove
between the intracellular segments of these helices. Molecular
dynamics simulations of FFAR1 with agonist removed demon-
strated a major rearrangement of the polar and charged anchor
point residues for the carboxylic acid moiety of the agonist in the
interhelical site, which was associated with closure of a neighbor-
ing, solvent-exposed pocket between the extracellular poles of TM-
I, TM-II, and TM-VII. A synthetic compound designed to bind in this
pocket, and thereby prevent its closure, was identified through
structure-based virtual screening and shown to function both as an
agonist and as an allosteric modulator of receptor activation. This
discovery of an allosteric agonist for a previously unexploited,
dynamic pocket in FFAR1 demonstrates both the power of includ-
ing molecular dynamics in the drug discovery process and that this
specific, clinically proven, but difficult, antidiabetes target can be
addressed by chemotypes different from existing ligands.
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The Gq-coupled free fatty acid receptor 1 (FFAR1/GPR40) isa clinically validated antidiabetes G protein-coupled receptor
(GPCR) target that binds medium- to long-chain fatty acids (C8–
C22) (1, 2) to stimulate gut hormone and insulin secretion (2–5).
In addition to the relatively broad group of endogenous lipid
ligands, many synthetic agonists have been developed, of which
several have entered clinical trials for the treatment of type 2
diabetes, as reviewed by Li et al. (6). Although most of these
ligands appear to share chemical properties, characterized by an
elongated topology and a terminal carboxylic acid group, mo-
lecular pharmacology studies have indicated the presence of
several mutually interacting binding sites in FFAR1 (7, 8). Cer-
tain synthetic agonists are, similar to the endogenous lipid ago-
nists, only able to induce Gq-like signaling, whereas other
agonists induce both Gq and Gs-like signaling, resulting in more
robust hormone responses. Radioligand binding experiments
have demonstrated that these two different types of FFAR1 li-
gands act as positive allosteric modulators, as they do not com-
pete for, but instead increase binding of, each other, indicating
that they act on distinct receptor sites (7).
Srivastava et al. (9) solved the X-ray crystal structure of
FFAR1 at 2.3 Å resolution in complex with the synthetic agonist
TAK-875 (PDB 4PHU), a previous clinical phase 3 drug candi-
date. This structure revealed a unique binding mode of TAK-875
compared with agonists in other GPCR structures. The elongated
hydrophobic part of the agonist was partly bound in a hydro-
phobic, tunnel-like interhelical site between transmembrane helix
(TM)-III and TM-IV, and partly extruded into the outer layer of
the lipid bilayer, suggesting entry from there. Importantly, the
carboxylic acid moiety of TAK-875 interacted directly with two
arginines (R183 and R258), as well as two tyrosines (Y91 and
Y240), which are part of an anchoring polar network at the
center of the receptor exposed to the extracellular space (Fig. 1).
Recently, Lu et al. (10) published two X-ray crystal structures of
FFAR1, one of them in complex with two agonists; that is, the
Gq-only synthetic agonist MK-8666 bound in the interhelical site
in a very similar manner as TAK-875 and the ago-allosteric modu-
lator AP8, bound in an open extrahelical, groove-like site located
between TM-III, TM-IV, and TM-V, facing the inner leaflet of the
lipid bilayer. Interestingly, in the previously published FFAR1
structure in complex with TAK-875 (9), and in several other
GPCR structures (11–13), this extrahelical site is occupied by either
a detergent or lipid molecule.
In all three published FFAR1 crystal structures, a third,
solvent-exposed pocket (termed site 3 in ref. 9) could be ob-
served between the extracellular poles of TM-I, TM-II, and TM-
VII; that is, on the opposite side of the polar network of residues
coordinating the carboxylic acid moieties of TAK-875 and MK-
8666 (Fig. 1A). This extracellular site is the main focus of the
present study, in which we investigated the structural dynamics of
FFAR1 in both the presence and absence of TAK-875 in the
interhelical site by use of all-atom classical molecular dynamics
(MD) simulations combined with metadynamics simulations.
Using experimental pharmacological testing of compounds, as
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well as mutational analyses, we describe an ago-allosteric mod-
ulator and highlight the extracellular site as an avenue for the
structure-based design of FFAR1 ligands.
Results
MD Simulations Reveal a Major Rearrangement of Polar Anchor-Point
Residues. Initially, we performed 600 ns of unbiased MD simu-
lations and compared representative frames that were obtained
by geometric clustering. Although FFAR1 is crystalized in
complex with agonists, the overall structure of the intracellular
part of the helical bundle of FFAR1 is rather similar to the
structure of various published inactive receptor conformations,
conceivably because of thermostabilizing mutations, which allow
for high-affinity agonist binding, but also prevent the receptor
from signaling in solution (9). In analogy to previous MD sim-
ulation studies of GPCRs in their inactive form (14, 15), we did
not observe any substantial change of the overall helical con-
figuration at the intracellular side, which remained similar to the
inactive-like state of, for example, the β2-adrenergic receptor
(16) (SI Appendix, Fig. S2A). However, during the course of the
MD simulation of FFAR1 in the presence of TAK-875, the in-
tracellular segment of TM-VI moved slightly (∼4 Å) toward TM-
V, which likely is related to the insertion of ICL3 in the FFAR1
model, which in the X-ray crystal structure is replaced with a
fusion protein (PDB 4PHU).
At the extracellular solvent-exposed face of the FFAR1 re-
ceptor, we observed a major rearrangement of residues of the
polar network during the MD simulations in the absence of
TAK-875, which was not observed in the presence of the stabi-
lizing carboxylic acid group of the agonist (Fig. 1 C and D). This
disruption lead to a substantial conformational change of not
only the side chains of the polar network but also a shifting
movement of the extracellular part of TM-I, TM-II, and TM-VII,
ultimately resulting in total closure (<10 Å3) of the solvent-
exposed extracellular site after ∼340 ns of simulation time
(Fig. 1 B and D). The movement of TM-VII was facilitated by
the structural flexibility induced by the proline of the conserved,
central NPxxY motif. In contrast to these changes observed in
the extracellular site, the hydrophobic tunnel-like part of the
interhelical TAK-875 site remained surprisingly stable after
the ligand had been removed (Fig. 1 B and D). We compared the
structural heterogeneity of all the MD trajectory structures by
geometric clustering of residues forming both the interhelical and
the extracellular site. Only 35 clusters were found for the trajec-
tory in the presence of TAK-875, and 64% of all trajectory con-
formations belonged to a single large cluster based on a 1 Å rmsd
cutoff. In comparison with this, more than a 100 different clus-
ters were identified for the trajectory in the absence of TAK-875.
This further illustrates the structural dynamics that occur in the
absence of TAK-875 (SI Appendix, Fig. S3).
Metadynamics Simulations of the Rearrangement of the Polar
Network. The MD simulations described here provide an un-
biased view of the dynamics of FFAR1. We supplemented these
by metadynamics simulations that allow us to map out the con-
formational free-energy landscape (17, 18). Thus, we estimated
the free-energy landscape for three selected collective variables
(CVs), chosen to represent the rearrangement of the polar net-
work as distances between key sidechains. Together, these CVs
describe the major conformational changes and exchange of in-
teraction partners we observed in the MD simulation in the
absence of TAK-875 (Fig. 1F): CV1 represents the separation of
the two positively charged guanidine groups of R183(Cζ) and
R258(Cζ) (from 3.5 Å in the X-ray crystal structure to 10.0 Å in
A
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Fig. 1. FFAR1 shows a third extracellular binding site
that is stabilized by the presence of the partial ago-
nist TAK-875. (A) FFAR1 in complex with TAK-875 and
AP8 docked into the interhelical site (PDB 4PHU). (B)
Pocket volume of the interhelical (yellow) and ex-
tracellular (blue) site over MD simulation time as 5 ns
running averages (solid line) and for every 0.2 ns
(faint line). (C and D) Comparison between repre-
sentative structures, obtained by 1 Å rmsd geometric
clustering from a 600 ns unbiased MD simulation in
the presence (snapshot at 171.40 ns) and absence
(snapshot at 493.24 ns) of TAK-875. (E and F) Rear-
rangement of the polar network stabilized by TAK-
875, as shown by representative structures from a
600-ns unbiased MD simulation of FFAR1 in the
presence and absence of TAK-875. Key amino acid
side chains involved in the polar network are shown
as purple sticks. (G–I) Free-energy profiles of selected
atomic distances (CV1-3) obtained by a well-tempered
metadynamics approach, using the same MD setup as
for the unbiased MD simulation in absence of TAK-875.
The free-energy profile was recorded every 10 ns, as
indicated by the color scale. The population of con-
formational states are indicated as percentages. The
corresponding atomic distances are displayed as black
dotted lines in F.
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the representative MD snapshot), CV2 describes the rotation of
Y240(OH) toward K62(Nζ) (from 8.67 Å to 4.5 Å), and CV3
indicates the formation of a salt bridge between R258(Cζ) and
E65(Cδ) (from 9.9 Å to 3.9 Å). During the metadynamics sim-
ulation, a time-dependent bias potential was introduced to dis-
courage previously visited conformations. Thermodynamic
reweighting provides access to the unbiased free energy as a
function of the simulation time to examine whether the observed
conformation represents energetic “trapping” resulting from in-
sufficient sampling or corresponds to a true global free-energy
minimum (17). In general, the global energy minima for the
three atomic distances that were chosen as CVs were in good
agreement with the atomic distances observed in the represen-
tative structures for the unbiased simulation absence of TAK-875
(CV1: 8.1 vs. 10.0 Å; CV2: 3.9 vs. 4.5 Å; CV3: 4.6 vs. 3.9 Å; Fig. 1
G–I). For CV2, a second, less occupied local minimum is present
at 9.5 Å, probably indicating a second stable rotamer of Y240.
However, when plotting the 2D free-energy plots for each of the
combinations of the three collective variables (SI Appendix, Fig.
S3), it is apparent that on rotation of Y240 toward K62, shown by
a shift to a lower value of CV2 at 3.9 Å, the free-energy land-
scape for CV1 and 3 converges into single minima at 8.1 Å and
4.6 Å, respectively. This suggests that the rotation of Y240 sta-
bilizes the formation of the salt bridge between R258 and E65
and keeps R183 and R258 separated. Overall, these results point
to a distribution of conformational states in which the rearranged
polar network (Fig. 1F) leading to the closure of the extracellular
site is in fact the dominant conformation in absence of TAK-875.
The conformational dynamics and apparent connectivity be-
tween the different FFAR1 binding sites prompted us to in-
vestigate whether the closure of the extracellular site is
reversible. The addition of TAK-875 after 600 ns of unbiased
MD simulation in fact causes a reopening of this site, causing the
pocket volume to rise from <10 Å3 to ∼100–250 Å3 (SI Appendix,
Fig. S1). Likewise, the associated relocation of TM-I, TM-II, and
TM-VII to their initial position (SI Appendix, Fig. S1B) leads to a
Cα-rmsd decrease from 2.8 Å (representative structure from the
MD simulation in absence of TAK-875) to 1.8 Å for the MD
simulation in which TAK-875 was added after 600 ns, compared
with the X-ray crystal structure of FFAR1 (PDB 4PHU). As a
consequence, the observed structural connectivity appears to be
based on a concerted dynamic allosteric mechanism in which the
presence of an agonist in the interhelical site is associated with
formation of a relatively large well-defined pocket; that is, the
extracellular site on the opposite side of the polar network (Fig.
1E). The observed structural dynamics of this part of the re-
ceptor leads to the hypothesis that prevention of the closure of
the extracellular site through binding of a ligand specifically
designed for this site would stabilize the active conformation
by preventing the receptor from moving into the presumably
inactive conformation, and consequently would function as
an agonist.
Structure-Based Design of an Ago-Allosteric Modulator.Accordingly,
we probed the extracellular site by conducting a structure-based
virtual screening of >12 million commercially available small
synthetic compounds (Fig. 2). These compounds were each
docked in two steps into an ensemble of four representative
structures from the unbiased MD simulation in the presence of
TAK-875, and filtered on the basis of general chemical criteria
and docking scores (19). A library of the 99 best-scored com-
pounds was acquired and tested for their ability to activate
FFAR1-mediated signal transduction in transfected HEK293
cells. Compound 1 (ZINC9634346/Z18477911), a derivative of
1,3,5-triazine-2-amine (Fig. 3C), was the most efficacious, with
similar potency and efficacy as the endogenous ligand, oleic acid
(Fig. 3A). Radiolabeled competition binding experiments
showed that Compound 1, in contrast to unlabeled TAK-875, was
unable to displace [3H]TAK-875 from the receptor, indicating that
this agonist can bind simultaneously with an agonist binding to the
interhelical site, in agreement with its expected binding in the
extracellular site (Fig. 3B). We then tested the ability of Com-
pound 1 to modulate activation of FFAR1 by oleic acid and the
two different types of synthetic agonists, TAK-875 and AM-5262
(Fig. 3 D–F). Compound 1 acted not only as an agonist but also as
an allosteric modulator by increasing the potency of oleic acid
∼32-fold and increasing its efficacy (Emax) with 34% at 100 μM of
Compound 1 (Fig. 3D). However, although increasing the potency
of TAK-875 and AM-5262 by fivefold and twofold, respectively,
Compound 1 surprisingly had a negative effect on the efficacy of
these two agonists; that is, reducing their Emax by 22% and 35%,
respectively (Fig. 3 E and F). Thus, Compound 1 acts as a positive
allosteric modulator on the endogenous lipid agonist, with respect
to both potency and efficacy, but increases the potency of the two
types of synthetic agonist types only slightly, and even decreases
their maximal efficacy. In this context, it is probably important to
note that the maximal efficacy of Compound 1 itself is less than that
of TAK-875 and AM-5262 (Fig. 3A). Therefore, it seems possible
that Compound 1, by stabilizing the extracellular site, is shifting the
dynamic equilibrium to an “active-like” conformation that can be
described as an intermediate between the conformations induced
by oleic acid, TAK-875, and AM-5262.
During follow-up experiments, we acquired 96 commercially
available analogs of Compound 1, which were subsequently experi-
mentally screened in an inositol phosphate (IP) accumulation assay.
We initially identified two compounds, the γ-lactam ZINC7064600/
Z107326816 and the ester-linked 3-methyl-7-fluorobenzofurane
ZINC45546728/Z154646582, with similar pharmacological activity
as Compound 1 (SI Appendix, Fig. S7). In general, the available an-
alogs were chemically rather diverse, especially around the coumarin
O 2 4 6 8 0 2 4 6 8 0 2 4 6 8 0 2 4 6 8 0 2 4 6 8 0 3 5 7 9 3 5 7 9 3 5 7 9 3 5 7 9 3 5 7 9 9 7 5
A B
Fig. 2. Structure-based discovery of Compound 1.
(A) Ligand screening approach used in this study. The
best-scored 100.000 compounds from a virtual screen-
ing of the In Stock subset of the ZINC database were
docked into an ensemble of representative FFAR1
structures retrieved from a 600-ns MD trajectory. After
applying further filtering criteria, a library of 99 com-
pounds was purchased and experimentally tested in
an IP accumulation assay. (B) Docking pose of Com-
pound 1 in FFAR1. Polar receptor-ligand interactions
are indicated with yellow spheres.
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motif and the attached ether linker, which was only present in three
of 96 compounds. We performed a more systematic exploration
of the structure–activity relationship, based on custom-made
synthesis (SI Appendix, Fig. S8). We found several active
compounds with improved potency and efficacy, among which
the meta- substituted Compounds 4 and 5 showed the highest
EC50 values of ∼1 μM. It was also possible to replace the cou-
marin motif in Compound 1 with an ester-linked 3-methyl-7-
fluorobenzofuran (Compound 6) moiety to achieve a modest
potency gain at the cost of some loss of efficacy.
To rule out colloid aggregation-based activation, we tested the
ability of Compound 1 to inhibit AmpC β-lactamase (SI Ap-
pendix, Fig. S9). At 31.6 μM concentration, the compound
showed 0.4% enzyme inhibition, comparable to TAK-875 and
well below the level of known aggregators, such as tetra-
iodophenolphthalein (16.66%) (20). Further, Compound 1 did
not show any unspecific activity on mock-transfected cells (SI
Appendix, Fig. S10).
To verify the binding sites and mode of action of the three
different types of synthetic agonists, we introduced a series of,
respectively, four, two, and seven mutations in the suspected
extrahelical, intrahelical, and extracellular binding sites and
tested the ability of the agonists to activate FFAR1, as listed in
SI Appendix, Table S1 and shown for key selected mutations in
Fig. 4. A very clear result was obtained by steric hindrance mu-
tation, A83F, in the hydrophobic tunnel of the interhelical site,
which, as expected, impaired the potency of TAK-875 consid-
erably (i.e., 1,740-fold; Fig. 4A), without affecting the function of
AM-5262 or Compound 1 (Fig. 4 C and D). Conversely, muta-
tions in the lipid-exposed extrahelical site impaired the potency
of AM-5262 as anticipated, without affecting TAK-875, as shown
for Y44F (Fig. 4 A and D). However, two of the mutations in the
extrahelical site (Y114F and S123A) unexpectedly decreased the
potency and efficacy of Compound 1 (Fig. 4C and SI Appendix,
Table S1), although this less lipophilic compound is expected to
act through binding to the extracellular site distant from the
mutations in the lipid-exposed extrahelical site. Although the
possibility of Compound 1 binding to the extrahelical site cannot
be excluded, the other two mutations in this site (Y44F and
G95F) actually improved potency of Compound 1 while dra-
matically decreasing potency of AM-5262. Specifically, the bulky
phenylalanine, which is introduced for G95, is located in a cen-
tral position in the extrahelical site and would be expected to
occupy a large section of this pocket. This steric hindrance mu-
tation has a major effect on the pharmacologic activity of AM-
5262 (67-fold potency decrease), as well as the positive allosteric
modulator AP8 (10), but remarkably, it has an unexpected pos-
itive effect on the activity of Compound 1, roughly doubling both
its potency and efficacy. This observation might be related to an
effect on a potential allosteric network that controls the dynamic
structural connectivity between these two sites. A similar finding
has been described in a mutational mapping study involving the
M1 and M4 muscarinic receptors, in which mutation of a large
number of residues involved in an allosteric network, but not in
direct ligand contact, led to reduction of the activity of the
positive allosteric modulator LY2033298 (21, 22).
This notion of an allosteric connectivity between the three
FFAR1 binding sites was further supported by the mutational
analysis of the extracellular site (Fig. 4 and SI Appendix, Table
S1), in which all seven mutations had a profound effect on the
activity of Compound 1, ranging from 34.6% reduction of Emax
(K259A) to a complete loss of activity (K259W, A66W, and
Y12W). However, we also observed that several of these muta-
tions impaired the potency of, in particular, TAK-875 (400–500-
fold decrease), and in one case (K259W) also decreased the
potency of AM-5262 (20-fold). A single mutation (K259A) could
be identified that selectively affected the efficacy of Compound 1
without affecting the two other compounds (blue curves in Fig. 4
A, C, and D). Because of their size and lipophilicity, it is not
conceivable that TAK-875 or AM-5262 bind to the solvent-
exposed extracellular site, also with respect to the crystallo-
graphically confirmed binding mode of TAK-875 in the tunnel-
like interhelical site. It is more likely that the close proximity
between these two sites (L262 is, e.g., a close neighbor to R258, a
residue in direct contact with TAK-875) is the underlying cause
for the observed effects, and that inserting a mutation into the
extracellular site affects affect the dynamic coordination of the
neighboring polar network required for anchoring the carboxylic
acid moiety of the TAK-875 ligand.
A B C
D E F
Fig. 3. Pharmacologic profile of Compound 1. (A) Dose–response curves of Compound 1 in comparison with known synthetic and endogenous FFAR1 ag-
onists. (B) Radiolabeled ligand binding of [3H]TAK-875 in combination with Compound 1. (C) Chemical structure of Compound 1 (D–F) Dose–response curves
of Compound 1 alone and in combination (10 and 100 μM fixed concentration) with oleic acid, TAK-875, and AM-5262. Values for log EC50, efficacy, and
potency fold-changes are indicated for each compound in the table (Right).
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Discussion
The main discovery of the present study is that an extracellularly
facing, solvent-exposed empty pocket, present in all three
agonist-bound X-ray crystal structures of FFAR1, closes during
MD simulations on removal of the prototype agonist TAK-875
from its interhelical site, and that a ligand designed to occupy the
extracellular pocket functions as an agonist and allosteric mod-
ulator of the receptor. Compound 1 has been designed to bind to
the extracellular site, and by presumably preventing the closure
of this pocket, it might stabilize an active, signaling conformation
of the receptor. In this case, Compound 1 was identified on the
basis of its favorable docking score (−28.04) in a representative
receptor conformation originating from the largest cluster from
the 600-ns MD trajectory in the presence of TAK-875. Docking
of Compound 1 into the unrefined X-ray crystal structure (PDB
4PHU), in contrast, resulted only in a score of −18.37, well
above the chosen cutoff (−25.00) that was applied in the virtual
screening protocol. The MD simulations were thus necessary for
the identification of Compound 1, which might underline the
importance of accounting for receptor dynamics in structure-
based drug discovery efforts and the potential of using MD
simulations to study the dynamics of unexploited pockets, which
deliberately can be targeted.
Although rational drug design efforts for GPCRs have tradi-
tionally focused on pockets between the extracellular segment of
the transmembrane helices and loops (23), a number of recent
X-ray crystal structures has revealed that ligands in fact can act
as agonists or antagonists through binding to multiple alternative
sites in the receptors. This includes allosteric sites located more
superficially between the extracellular loops (24); extrahelical
sites in the transmembrane region (25), similar to the binding
site of AP8 in FFAR1 (10); or even sites at the intracellular face
of the receptor, involving interactions with the intracellular poles
of the TMs as well as ICL1 and helix 8 (26). This is in accordance
with hypotheses dating more than 2 decades ago, in which it was
proposed that GPCRs would have multiple different agonist
binding sites, based on the notion that an agonist did not have to
interact with a specific active site, but only needed to stabilize an
active conformation of the dynamic receptor structure (27).
FFAR1 is a prime example of this, as it appears to possess at
least three very distinct binding sites for agonists: the interhelical
site for the hydrophobic para-substituted O-phenyl-alkyl acids,
such as TAK-875 and MK-8666; an extrahelical lipid-exposed site
for meta-substituted O-phenyl-alkyl acids, such as AM-5262 and
AP8; and a solvent-exposed extracellular site with more polar
properties (Fig. 4). It is, however, still unclear to which sites the
endogenous long-chain fatty acid (LCFA) agonists, including the
newly identified 20-HETE (28, 29), bind, as they readily can be
docked into both the interhelical and the extrahelical site (SI Ap-
pendix, Fig. S4) (7). From a signal transduction point of view, en-
dogenous LCFAs function as Gq-only agonists (i.e., similar to TAK-
875 and MK-8666), which would indicate that the interhelical
binding site is the orthosteric site. Further, it is possible, and even
likely, that two LCFA molecules may in fact bind to FFAR1 at the
same time, and access both the inter- and extrahelical sites via the
lipid bilayer. This might also be the case for some of the synthetic
agonists, such as AM-5262, as they dock very well into both sites (7).
In contrast, the extracellular solvent-exposed site is more
solvent-exposed and of a rather polar character, as well as a
different shape, in relation to both of the two other agonist
binding sites, and it is unlikely that ligands binding to either the
extrahelical or the interhelical site are able to act on the extra-
cellular site as well. Compared with other GPCRs with crystal-
lographically resolved allosteric binding sites, such as the
muscarinic M2 receptor with its modulator binding site in the
extracellular vestibule (24), FFAR1’s extracellular site is located
in a partially overlapping location, but slightly smaller in size (30)
and of more polar character. The M2 allosteric binding site is
largely preformed in the presence of an agonist, similar to the
stabilizing effect that we observed for the extracellular allosteric
pocket in FFAR1 during the MD simulations in the presence
of TAK-875.
The MD simulations of FFAR1 suggested that the presence of
the agonist TAK-875 in the interhelical site between the extra-
cellular segments of TM-III and TM-IV induced a helical con-
formation of ICL2, connecting the intracellular poles of these
two helices. Secondary structure analysis of ICL2, which initially
started in a random coil conformation, revealed that it was more
likely to adopt an α-helical conformation in the presence (32%
of all ICL2 residues over all frames) than in the absence (6%) of
TAK-875 (SI Appendix, Fig. S1 A and B). This long-range allo-
steric effect appeared to be related to the relatively tight binding
of the octadecanoyl tail of a 1-palmitoyl-2-oleoyl-sn-glycero-3-
phosphoethanolamine molecule from the artificial membrane
in the extrahelical groove between the intracellular segments of
TM-III and TM-IV over the entire simulation time in a similar
binding mode as the crystallographic pose of AP8 in FFAR1
(PDB 5TZY). A helical conformation of ICL2 has been ob-
served in many X-ray crystal structures of agonist-bound GPCRs,
and appears to be associated with active-state receptor confor-
mations and interactions with the G proteins (16). Therefore, the
extrahelical site of FFAR1 might play a role in stabilizing the
important helical formation of ICL2. It is likely that this extra-
helical site could function as an allosteric binding site in many
other GPCRs, as a similar binding groove is found in many
structures of GPCRs and is often occupied with a lipid or de-
tergent molecule (11, 31, 32).
Compound 1 represents an exciting starting point for a dif-
ferent type of FFAR1 ago-allosteric modulators, with respect to
both chemotype and allosteric mechanism, which could translate
into alternative therapeutic strategies for the treatment of type 2
diabetes (29, 33). The modulator properties of Compound 1
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Y44F
A B C
D Fig. 4. Mutational analysis of the interplay between
FFAR1’s three binding sites. (A, C, andD) Dose–response
curves of the receptor mutants K259A, A83F, and Y44F
are shown for TAK-875, AM-5262, and Compound 1,
respectively. (B) Surface/cartoon representation of
FFAR1 (PDB 5TZY) with the three binding sites indi-
cated. Docking poses for TAK-875 (orange), AM-5262
(green), and Compound 1 (blue) are shown in stick
representation. The location of key mutations tested
in this study is marked in purple.
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might further enable a more fine-tuned effect on physiological
signaling while maintaining the spatial and temporal attributes of
endogenous free fatty acid ligands (34).
Materials and Methods
MD Simulations. All MD simulations were performed in GROMACS 4.6.5 (35),
using the CHARMM36 force field (36) and the TIP3P water model. The X-ray
crystal structure of FFAR1 (PDB 4PHU) was embedded into a 50-ns pre-
equilibrated palmitoyl-2-oleoylsn-glycero-3-phosphatidylcholine membrane,
using g_membed (37). After solvation in a cuboid box, Na+ and Cl− ions were
added to neutralize the overall electric charge and to model an ion con-
centration of 0.15 M. A steepest-descent energy minimization was con-
ducted and the system containing TAK-875 was equilibrated in the NPT
ensemble for 40 ns, using decreasing position restraints. Representative
structures for the extracellular and interhelical sites were selected by per-
forming a geometric clustering based on the 48 residues that form the ex-
tracellular site and the interhelical binding site for TAK-875 and MK-8666,
using a Cα-rmsd cutoff value of 1 Å to determine cluster membership (SI
Appendix, Fig. S3). Well-tempered metadynamics simulations were per-
formed in GROMACS 5.1.2/PLUMED 2.2.1 (18) using the MD setup described
above. We obtained the free-energy profiles of three selected atomic dis-
tances: CV1 = E65(Cδ)-R258(Cζ), CV2 = Y240(OH)-K62(Nζ), and CV3 = E65(Cδ)-
R258(Cζ) (atom naming according to PDB standard). Additional details are
included in the SI Appendix.
Molecular Docking and Virtual Ligand Screening. We docked the In Stock
subset of the ZINC database (38), using SurflexDock (version 2.5) (39), into
FFAR1’s extracellular site. The 100,000 best-scored compounds (prefiltered
for crash score >−2, polar score >2) were selected for a second docking
protocol, using ICM 4D docking and an ensemble of four representative
receptor structures (version 3.8–4a; Molsoft L.L.C.). A set of chemical filtering
criteria was applied (MW ≤ 500, logP ≤ 5, nrotb ≤ 12, VLS score ≤−25, drug
likeness score ≥0.2, internal ligand conformation energy ≤10) to yield 315
compounds from which a small library of 99 compounds was cherry-picked.
Additional details are included in the SI Appendix.
Experimental Functional and Binding Studies. FFAR1 was cloned into the ex-
pression vector pCMV-Tag 2B encoding a N-terminal FLAG tag epitope
(Stratagene), using the QuikChange method. COS7 cells were transfected
using calcium phosphate precipitation method. IP accumulation assays were
conducted as described by Hauge et al. (7). Competition binding assays were
performed by adding increasing doses of TAK-875 and Compound 1 to the
binding buffer (Hepes wash buffer + 100 μg/mL bacitracin), and immediately
after, 50 μL tracer solution containing 3H-TAK-875 (5,000 cpm/well) was
added. Plates were incubated for 3 h and washed twice, and γ-radiation was
counted on a Packard Top Count NXT counter. Additional details are in-
cluded in the SI Appendix.
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